文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

慢病毒载体α-珠蛋白基因治疗输血依赖型α-地中海贫血首例成功报告

Successful gene therapy for transfusion-dependent α-thalassemia: a case report.
PubMed 文献 · Blood Adv · 2026-01-01

本文报告首例人源慢病毒载体介导的α-珠蛋白基因治疗用于14岁输血依赖型HbH病女孩(--SEA/αCSα)。经busulfan预处理后回输基因修饰的自体CD34+细胞,患者3周内植入、第4周起脱离输血,随访第12-24个月平均Hb约90 g/L且HbA占比>85%,载体拷贝数稳定,无克隆优势或插入突变证据,安全性可行。

要点

  • 首例人源慢病毒α-珠蛋白基因治疗使输血依赖型HbH病患者脱离输血。
  • 随访第12-24个月平均Hb约90 g/L,HbA占总Hb>85%。
  • 未检测到克隆优势、插入突变或复制 competent 慢病毒。

核心结论

  • 慢病毒载体介导的α-珠蛋白基因治疗对输血依赖型α-地中海贫血展示出可行性、安全性和持久疗效,可能成为潜在治愈手段。

研究设计与样本

  • 病例报告:14岁女性输血依赖型HbH病(--SEA/αCSα),接受慢病毒载体(Lenti-HBA)修饰的自体CD34+造血干/祖细胞回输,busulfan预处理。
  • 临床试验注册号NCT05851105。

主要发现

  • 患者3周内实现植入,自第4周起脱离输血。
  • 随访第12-24个月平均Hb水平维持约90 g/L,HbA占总Hb>85%。
  • 载体拷贝数稳定,未检测到克隆优势、插入突变或复制 competent 慢病毒。
  • 不良事件限于预期的busulfan相关毒性,包括2级月经不规则和卵巢早衰(严重不良事件)。
  • 停止祛铁治疗后铁过载进展轻微,未发生心脏铁沉积;免疫恢复、生长发育保持。

临床怎么用

  • 对于无合适供者的输血依赖型α-地中海贫血患者,慢病毒α-珠蛋白基因治疗可能提供一种潜在治愈选择。
  • 治疗相关毒性主要为busulfan预处理相关,需关注性腺毒性等远期影响。

局限性

  • 单例病例报告,随访时间有限(至24个月),长期疗效和安全性仍需更多患者和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

α-Thalassemia is a severe inherited hemoglobin (Hb) disorder with limited curative options for patients with transfusion dependency, lacking suitable donors. We report, to our knowledge, the first-in-human application of lentiviral vector-mediated α-globin gene therapy in a girl aged 14 years with transfusion-dependent HbH disease (--SEA/αCSα). Autologous CD34+ hematopoietic stem and progenitor cells were mobilized, collected, and genetically modified ex vivo using the lentiviral vector (Lenti-HBA) to restore α-globin expression, then reinfused after busulfan conditioning. The patient achieved engraftment within 3 weeks and started to be free of transfusions from the fourth week onward. In the last year of follow-up (months 12-24), the average Hb level remained at ∼90 g/L without transfusion support, with HbA accounting for >85% of total Hb. Vector copy numbers were stable, and no evidence of clonal dominance, insertional mutagenesis, or replication-competent lentivirus was detected. Adverse events (AEs) were limited to expected busulfan-related toxicities, including grade 2 menstrual irregularity and ovarian failure (serious AE). Despite cessation of chelation therapy, iron overload progressed minimally, and no cardiac iron deposition occurred. Immune recovery, growth, and development were preserved. This case demonstrates the feasibility, safety, and durable efficacy of lentiviral α-globin gene therapy as a potential curative treatment for transfusion-dependent α-thalassemia. This trial was registered at www.clinicaltrials.gov as NCT05851105.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yin X, Qian L, Dong G, et al. Successful gene therapy for transfusion-dependent α-thalassemia: a case report. Blood Adv. 2026. PMID: 42200456. doi:10.1182/bloodadvances.2025019280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。